



Sunday / May 31, 2020

13:00 - 16:00				
	Breast / Gynecology	Presented by: Prof. Dr. med. Thomas Kunz, PD Dr. med. Christian Kurzeier, Dr. med. Andreas Müller, PD Dr. med. Khalil Zaman, PD Dr. med. Michael Knauer Live experts: Dr. Stefanie Hayoz, Prof. Dr. med. Wolfram Jochum, PD Dr. med. Ulf Petrusch, Prof. Dr. med. Daniel R. Zwiahlen		
Abstract no	Entity	First Author	Titel	Link to the video
500	Breast early	Harbeck	Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).	https://meetinglibrary.asco.org/record/184902/video
Discussion				
501	Breast early	van der Voort	Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.	https://meetinglibrary.asco.org/record/184908/video
Discussion				
507	Breast early	Wang	Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).	https://meetinglibrary.asco.org/record/184912/video
Discussion				
1000	Breast metastatic	Cortes	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.	https://meetinglibrary.asco.org/record/184800/video
Discussion				
1003	Breast metastatic	Xu	Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.	https://meetinglibrary.asco.org/record/184810/video
Discussion				
1005	Breast metastatic	Lin	Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).	https://meetinglibrary.asco.org/record/185141/video
Discussion				
1006	Breast metastatic	Rugo	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.	https://meetinglibrary.asco.org/record/186927/video
Discussion				
6000	Gynecologic Cancer	Du Bois	Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.	https://meetinglibrary.asco.org/record/185438/video
Discussant	Gynecologic Cancer	Coleman	Discussion	
Discussion				
6007	Gynecologic Cancer	Huang	Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.	https://meetinglibrary.asco.org/record/185461/video
Discussion			and Wrap-up	
Plenary LBA 2	Breast metastatic	Khan	A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108).	https://meetinglibrary.asco.org/record/186884/abstract

Organizer



Founding Sponsor



Roche Pharma (Schweiz) AG
4052 Basel

Co-Sponsors

